

**NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE**

**TECHNOLOGY APPRAISAL PROGRAMME**

**Equality impact assessment – Scoping**

**STA Autologous anti-CD19-transduced CD3+ cells for treating relapsed or refractory B-precursor acute lymphoblastic leukaemia in adults  
[ID1494]**

**The impact on equality has been assessed during this appraisal according to the principles of the NICE Equality scheme.**

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

Leukaemia Care stated that NICE should address the potential discrimination on age restrictions in the CAR-T therapies.

2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?

The committee can only appraise the topic within its marketing authorisation.

3. Has any change to the draft scope been agreed to highlight potential equality issues?

No

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the matrix been made?

No

**Approved by Associate Director (name):** Jasdeep Hayre

**Date:** 20/09/21